Product
177Lu-AB-3PRGD2
2 clinical trials
2 indications
Indication
Solid TumorIndication
Integrin αVβ3 Positive TumorsClinical trial
An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Effectiveness of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive ExpressionStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive TumorsStatus: Recruiting, Estimated PCD: 2024-10-30